Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy
EXCLI Journal · 28.08.2025 · 24 · 1100-1142
DOI: 10.17179/excli2025-8735 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 28.08.2025. Verfasst von Alaa A A Aljabali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid, 21163, Jordan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study investigated the therapeutic impact of dual immune checkpoint inhibition targeting TIGIT and VISTA in non-small cell lung cancer (NSCLC). Current monotherapies have failed to produce consistent and durable responses owing to tumor heterogeneity and immune evasion. By evaluating the biological and immunomodulatory roles of TIGIT and VISTA, this study provides a rationale for their simultaneous blockade. Preclinical models have shown that this dual strategy not only revitalizes T-cell function but also alters the suppressive tumor microenvironment, leading to improved antitumor immunity in mice. Preliminary clinical data suggest potential survival benefits; however, the long-term outcomes and resistance dynamics remain uncertain. These findings suggest a paradigm shift toward precision-designed, multi-target immunotherapies. Future studies should integrate molecular profiling, adaptive clinical trial designs, and follow-up models to optimize patient selection and sustain therapeutic benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, P.O. Box 566, Irbid, 21163, Jordan.
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, PO BOX 566, Irbid, 21163, Jordan.
- Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
- School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab) 144411, India.
- School of Bioengineering and Biosciences, Lovely Professional University, Phagwara (Punjab) 144411, India.
Zitieren
APA
Aljabali, A. A. A., Gammoh, O., Qnais, E., Alqudah, A., Mishra, V., Mishra, Y., & El-Tanani, M. (2025). Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy. EXCLI Journal, 24, 1100-1142. https://doi.org/10.17179/excli2025-8735
Vancouver
Aljabali AAA, Gammoh O, Qnais E, Alqudah A, Mishra V, Mishra Y, et al. Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy. EXCLI Journal. 2025;24:1100-1142. doi:10.17179/excli2025-8735
BibTeX
@article{Aljabali2025,
author = {Aljabali, Alaa A A and Gammoh, Omar and Qnais, Esam and Alqudah, Abdelrahim and Mishra, Vijay and Mishra, Yachana and El-Tanani, Mohamed},
title = {Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {1100--1142},
doi = {10.17179/excli2025-8735}
}
EUVIMED